You are here: Industry Insights > JMB2002

News List

Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002 prnasia
January 04, 2022
Joint research results from Biologics of Jemincare and Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002...
Jemincare group has completed the Phase I clinical trial of its anti-SARS-CoV-2 neutralizing antibody JMB2002 prnasia
September 23, 2021
Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002).
US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002 prnasia
April 02, 2021
On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.
Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant prnasia
February 09, 2021
On February 7, 2021, scientists from Jemincare Shanghai Research Institute published a preprint paper on BioRxiv, the paper entitled "A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed ...
Jemincare initiates phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002 prnasia
January 20, 2021
On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002).